Anti-Human CD40 (Clone HB-14) – Purified in vivo GOLD^TM Functional Grade

Recombinant protein of CD40 protein

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2-8°C Wet Ice

Clone HB-14 recognizes human CD40.

CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors.

CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen-presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation, and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy; blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific to human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus playing a significant part in Alzheimer's disease pathogenesis.

The anti-CD40 HB-14 clone was generated as part of a panel submitted to the Fifth International Leukocyte Differentiation Antigen Workshop¹.

CD154 (CD40 ligand)

1. Katira A, Holder MJ, Pound JD, and Gordon J. 1995. CD40 Workshop Panel Report. In Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, and Todd RF, eds, Leukocyte Typing V, p. 547. Oxford University Press, Oxford.
2. Herbert J. Thesis: The regulation of specific antibody secretion by human B cells through contact and non-contact dependent mechanisms. 1996. https://discovery.ucl.ac.uk/id/eprint/10100666/1/out.pdf
3. Zhou LJ, Tedder TF. Proc Natl Acad Sci U S A. 93(6):2588-2592. 1996.
4. Tan PH, Beutelspacher SC, Xue SA, et al. Blood. 105(10):3824-3832. 2005.
5. Iwata Y, Matsushita T, Horikawa M, et al. Blood. 117(2):530-541. 2011.
6. Bacher P, Schink C, Teutschbein J, et al. J Immunol. 190(8):3967-3976. 2013.
7. Bacher P, Heinrich F, Stervbo U, et al. Cell. 167(4):1067-1078.e16. 2016.
8. Mura M, Chaudhury S, Farooq F, et al. MethodsX. 22;7:101005. 2020.
9. Pound JD, Challa A, Holder MJ, et al. Int Immunol. 11(1):11-20. 1999.